GLPwatch
Papers (12034)
Page 22 of 201, ranked by citation count.
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
- Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
- Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.
- Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.
- Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.
- Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.
- Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.
- Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
- Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.
- Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.
- Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
- GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.
- Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.
- Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
- Glucagon and heart in type 2 diabetes: new perspectives.
- Psychological and quality of life changes in patients using GLP-1 analogues.
- Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Weight beneficial treatments for type 2 diabetes.
- Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System.
- Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.
- Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.
- The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
- The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease.
- Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.
- Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
- Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.
- Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
- Exendin-4 improves β-cell function in autophagy-deficient β-cells.
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
- Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
- Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.
- The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
- Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.
- Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.
- GLP-1 and Its Analogs: Does Sex Matter?
- Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.
- Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.
- Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.
- Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.
- Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.
- Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.
- Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.
- Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.
- Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.
- Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.
- Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.
- Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
- Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
- Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.